Short-term effect of tibolone on C-reactive protein in hypertensive postmenopausal women

Archives of Gynecology and Obstetrics

Volumn 279, Issue 3, 2009, Pages 305-309

  Engin Üstün, Yaprak ^a   Üstün, Yusuf ^a   Türkçüoǧlu, Ilgin ^a   Mutlu Meydanli, M ^a   Kafkasli, Ayşe ^a   Yetkin, Gülay ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Hypertension; Menopause; Tibolone

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; TIBOLONE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MAMMOGRAPHY; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; VASOMOTOR REFLEX;

ANTIHYPERTENSIVE AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; STATISTICS, NONPARAMETRIC; TRIGLYCERIDES;

EID: 58849099920     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-008-0712-6     Document Type: Article

References (28)

1. JF Barnes E Farish M Rankin DM Hart 2002 A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors Atherosclerosis 160 185 193 10.1016/S0021-9150(01)00560-3
2. JF Barnes E Farish M Rankin DM Hart 2005 Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine Menopause 12 92 98 10.1097/00042192-200512010-00016
3. NH Bjarnason K Bjarnason J Haarbo HJ Bennink C Christiansen 1997 Tibolone: influence on markers of cardiovascular disease J Clin Endocrinol Metab 82 1752 1756 10.1210/jc.82.6.1752
4. C Castelo-Branco E Casals F Figueras A Sanjuan JJ Vicente J Balasch 1999 Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B Menopause 6 92 97 10.1097/00042192-199906020-00004
5. S Davison SR Davis 2003 New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy J Clin Endocrinol Metab 88 2470 2478 10.1210/jc.2002-021929
6. AL Eilertsen L Sandvik B Steinsvik PM Sandset 2008 Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers J Thromb Haemost 6 928 934 10.1111/j.1538-7836.2008.02970.x
7. P Garnero C Jamin CL Benhamou C Pelissier C Roux 2002 Effects of tibolone and combined 17β-estradiol and norethisterone acetate on serum C-reactive protein in healthy postmenopausal women: a randomized trial Hum Reprod 17 2748 2753 10.1093/humrep/17.10.2748
8. W Hanggi K Lippuner W Riesen P Jaeger MH Birkhauser 1997 Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomized study Br J Obstet Gynaecol 104 708 717
9. Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure 2003 The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA 289 2560 2572 10.1001/jama.289.19.2560
10. P Kenemans L Speroff International Tibolone Consensus Group 2005 Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group Maturitas 51 21 28 10.1016/j.maturitas. 2005.02.011
11. H Kiran G Kiran 2006 Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women Arch Gynecol Obstet 274 9 12 10.1007/s00404-005-0111-1
12. G Lloyd E McGing A Cooper N Patel PJ Lumb AS Wierzbicki 2000 A randomized placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women J Hum Hypertens 14 99 104 10.1038/sj.jhh.1000938
13. A Mahmud J Feely 2002 Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition Am J Hypertens 15 321 325 10.1016/S0895-7061(01)02313-5
14. T Nada M Nomura K Koshiba T Kawano J Mikawa S Ito 2007 Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity Arzneimittelforschung 57 698 704
15. Y Nagatomo T Yoshikawa T Kohno A Yoshizawa T Anzai T Meguro 2007 Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure J Card Fail 13 365 371 10.1016/j.cardfail.2007.02.004
16. W Palmas S Ma B Psaty DC Goff Jr C Darwin RG Barr 2007 Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis Am J Hypertens 20 233 241 10.1016/j.amjhyper.2006.08.006
17. MB Pepys A Berger 2001 The renaissance of C reactive protein BMJ 322 4 5 10.1136/bmj.322.7277.4
18. GM Prelevic P Kwong DJ Byrne IA Jagroop J Ginsburg DP Mikhailidis 2002 A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women Fertil Steril 77 945 951 10.1016/S0015-0282(02)03078-9
19. PM Ridker CH Hennekens JE Buring N Rifai 2000 C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 836 843 10.1056/NEJM200003233421202
20. N Rifai PM Ridker 2001 Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening Clin Chem 47 28 30
21. LM Ruilope E Malacco Y Khder A Kandra G Bönner D Heintz 2005 Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study Clin Ther 27 578 587 10.1016/j.clinthera.2005.05.006
22. T Takeda S Hoshida M Nishino J Tanouchi K Otsu M Hori 2003 Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels Atherosclerosis 169 155 158 10.1016/S0021-9150(03)00158-8
23. M Todorova Z Kamenov V Christov M Baleva 2006 Inflammatory activity and anticardiolipin antibodies during tibolone treatment of healthy postmenopausal women Methods Find Exp Clin Pharmacol 28 147 149 10.1358/mf.2006.28.3.985168
24. RP Tracy RN Lemaitre BM Psaty DG Ives RW Evans M Cushman 1997 Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project Arterioscler Thromb Vasc Biol 17 1121 1127
25. WM Van Baal P Kenemans MJ Van der Mooren H Kessel JJ Emeis CD Stehouwer 1999 Increased C-reactive protein levels during short term hormone replacement therapy in healthy postmenopausal women Thromb Haemost 81 925 928
26. C Vitale A Cornoldi O Gebara A Silvestri M Wajngarten E Cerquetani 2005 Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy Menopause 12 552 558 10.1097/01.gme.0000172267.24949.70
27. A YIldIrIr F Aybar L Tokgozoglu H Yarali G Kabakci O Bukulmez 2002 Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels Gynecol Obstet Invest 53 54 58 10.1159/000049412
28. P Zandberg JLM Peters PN Demacker EG de Reeder MJ Smit DG Meuleman 2001 Comparison of the anti-atherosclerotic effect of tibolone with that of estradiol and ethynil estradiol in cholesterol-fed, ovariectomized rabbits Menopause 8 96 105 10.1097/00042192-200103000-00004